The global buffer preparation market, valued at USD 8.48 billion in 2025, is projected to reach USD 9.18 billion in 2026 and USD 17.96 billion by 2035, with a 7.7% CAGR during the forecast period 2026 to 2035. n January 2025, Medix Biochemica acquired CANDOR Bioscience to strengthen its portfolio of critical raw materials for the in vitro diagnostics (IVD) industry. North America is likely to capture the majority share (~40%) in the overall market in 2025, and this trend is unlikely to change in...

The mRNA synthesis and manufacturing market is estimated to be USD 0.56 billion in 2026. It is expected to reach USD 4.20 billion by 2035, representing a CAGR of 40.9% between 2028 and 2035. In June 2025, Ethris entered into a collaboration with Thermo Fisher Scientific, combining the former company’s comprehensive mRNA technology platforms with Thermo Fisher’s manufacturing capabilities, with an aim to advance mRNA therapeutics from research to clinical stages. In 2025, commercial scale sub...

The next generation antibody therapeutics market, valued at USD 4.94 billion in 2025, is projected to reach USD 5.45 billion in 2026 and USD 5.76 billion by 2035, with a CAGR of 1% during the forecast period 2026 to 2035. In June 2025, AbTherx entered into a collaboration with GPCR Therapeutics to discover and develop antibodies for novel GPCR targets. In 2025, immunotoxins segment holds most of the market share owing to their superior targeted cytotoxicity and effectiveness against resistant c...

The global B-cell Inhibitors market, valued at USD 21.2 billion in 2025, is projected to reach USD 24.6 billion in 2026 and USD 51.5 billion by 2035, with a 8.6% CAGR during the forecast period 2026 to 2035. In September 2025, Zenas BioPharma collaborated with Royalty Pharma for up to USD 300 million in funding for the development of Obexelimab for autoimmune disorders. The B-cell Inhibitors therapy pipeline analysis shows that 51% of the B-cell Inhibitors are currently in phase II of developme...

The medical device coatings market size is estimated to grow from USD 8.8 billion in 2025 to reach USD 9.4 billion in 2026 and USD 17.3 billion by 2035, representing a higher CAGR of 7.1% during the forecast period. The hydrophilic segment is likely to capture majority of the share (62%); further, this trend is likely to remain the same in the future as well. polymer-based coating material captures the highest market share (45.5%), further, this trend is likely to remain the same during the fore...

The global AI in drug manufacturing market is estimated to grow from USD 0.9 billion in 2025 to reach USD 1.2 billion in 2026 and USD 34.8 billion by 2040, representing a CAGR of 27.2% during the forecast period 2026 to 2040. In June 2025, Aizon entered into a partnership with Sequence aimed at delivering comprehensive, AI-powered solutions for the pharmaceutical industry. Based on the type of AI solution, the global market includes standard / off-the-shelf AI solutions and personalized AI solut...

The global RSV vaccine market size, valued at $1,149.41 million in 2025, is anticipated to reduce to $987.83 million in 2026 and $731.05 million by 2040. Respiratory Syncytial Virus (RSV) is a widespread virus that primarily affects the lower respiratory tract, leading to infectious diseases. In September 2024, WHO gave a global recommendation for maternal RSV immunization, with a single dose of RSV vaccine in the third trimester of pregnancy. As per WHO, around 33 million new cases of RSV disea...

The sustainable refrigeration technology market is estimated to grow from USD 69.4 billion in 2026 to reach USD 114.3 billion in 2032 and USD 211.5 billion by 2040, representing a higher CAGR of 8.3% during the forecast period. In 2026, the equipment sub-segment captures the majority (70%) of the overall market and is likely to grow at a higher CAGR of 8.35%.

The global anti-aging drugs market, valued at USD 79 million in 2025, is projected to reach USD 150 million in 2026 and USD 2,807 million by 2040, with a 23.3% CAGR during the forecast period 2026 to 2040. The National Institute of Health around 7.2 million American citizens aged above 65 and above live with diseases, such as Alzheimer. In January 2025, the Dog Aging Project secured a USD 7 million grant to expand its clinical trial of an anti-aging drug. It is worth highlighting that the mar...

The psychedelic drugs market is estimated to grow from USD 2.77 billion in 2024 to reach USD 3.19 billion in 2025 and USD 12.89 billion by 2035, representing a higher CAGR of 15% during the forecast period. In the same month, Cybin secured a $500 million financing deal with High Trail Capital, starting with a $50 million initial tranche to support late-stage psychedelic programs CYB003 and CYB004 for mental health disorders. In the same month, Filament Health announced positive data from phase 2...

The AI in oncology market is estimated to grow from USD 1.7 billion in 2024 to reach USD 2.4 billion in 2025 and USD 9.1 billion by 2035, representing a higher CAGR of 14.1% during the forecast period. Further, more than 35 million new cancer cases are likely to be diagnosed by 2050. According to the International Agency for Cancer Researchers, the number of cancer-associated deaths is likely to increase by 72%, by 2030. In February 2025, Myriad Genetics signed a strategic partnership with PATHO...

The vaccine development companies produced an estimated 7 billion doses of vaccines globally, in the year 2024 and are expected to produce around 8 billion doses in 2025. In January 2025, the Coalition for Epidemic Preparedness Innovations (CEPI) has made a significant new investment of $ 24 million in the Vaccine and Infectious Disease Organization (VIDO), aiming to bolster global preparedness for future infectious disease outbreaks as the world continues to recover from the last pandemic. Nota...

The targeted protein degradation market is estimated to grow from USD 0.48 billion in 2024 to reach USD 1.00 billion in 2025 and USD 6.94 billion by 2035, representing a higher CAGR of 21% during the forecast period. In June 2025, SEED Therapeutics announced the appointment of Dr. Bill Desmarais as the Chief Financial Officer and Chief Business Officer, who previously served as Chief Business Officer at Alchemab Therapeutics. In May 2025, Kesmalea Therapeutics appointed Tim Clackson to its board...

The biostimulants market is estimated to grow from USD 2.88 billion in 2024 to reach USD 3.18 billion in 2025 and USD 8.60 billion by 2035, representing a higher CAGR of 10.45% during the forecast period. The farm bill describes biostimulants as substances or microorganisms that stimulate natural processes to enhance nutrient uptake, nutrient efficiency, tolerance to abiotic stress, or crop quality and yield. In May 2025, TPG and Renaissance Partners jointly acquired a stake in SICIT. An Italy-...

Several market players are focusing on strategic initiatives to strengthen their product portfolio and expand innovation. For instance, in January 2025, Bayer Consume Health (Germany) launched, CanesMeno®, a unique science-backed product range and defined digital education resources crafted by the experts for the first time in the UK. The product is specifically designed to support health of 13 million women in the UK who are experiencing menopausal / premenopausal condition. Similarly, a lot o...

The global digital therapeutics market, valued at USD 3.53 billion in 2025, is projected to reach USD 4.47 billion in 2026 and USD 19.76 billion by 2035, with a 17.94% CAGR during the forecast period 2026 to 2035. With regards to type of therapy, the curative segment dominates the global market with 85% of the market share. Based on the purpose of solution, the medication replacement solutions segment holds the largest market share (nearly 65%). With respect to type of business model, B2B seg...

The global AAV vector market, valued at USD 3.0 billion in 2025, is projected to reach USD 3.7 billion in 2026 and USD 10.8 billion by 2035, representing a CAGR of 13% during the forecast period 2026 to 2035. In terms of type of manufacturer, contract manufacturer segment is estimated to capture majority of the AAV vector manufacturing market share, and this trend is unlikely to change in the future as well. In April 2026, FDA approved Otarmeni, the first dual adeno-associated virus vector-based...

The global vocal biomarkers market, valued at USD 2.56 billion in 2024, is projected to reach USD 2.98 billion in 2025 and USD 10.49 billion by 2035, with a CAGR of 13.4% during the forecast period 2025 to 2035. This market is growing steadily, driven by the growing recognition of voice analysis for disease diagnosis and monitoring. In terms of disease indication, neurological disorders segment currently holds over 70% of the market share due to the increasing usage of voice analysis for detecti...

The phosphoramidite market, valued at USD 1.0 billion in 2025, is projected to reach USD 1.1 billion in 2026 and USD 2.7 billion by 2035, with a 10.4% CAGR during the forecast period 2026 to 2035. In August 2025, the 4th Annual Oligonucleotide Analytical Development and CMC Summit is likely to be held with an aim to exchange insights on optimized analytical approaches to ensure high-quality oligonucleotide synthesis. In April 2025, Integrated DNA Technologies partnered with Elegen to offer the...

Considering the ongoing demand, the market players are undertaking initiatives to develop advanced assisted living technologies, specifically assistive robots. For instance, in July 2025, MIT engineers team have successfully built and tested an Elderly Bodily Assistance Robot (E-BAR), a form of mobile robot to physically support the elderly people and prevent them from falling. As market players continue to innovate advanced assistive robots, it is expected that eldercare assistive robots market...